The 3 Best Dividend Aristocrat Stocks in the First Half of 2022: Are They Buys Now?The Motley Fool • 07/01/22
Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of PossibilitiesPRNewsWire • 06/27/22
CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial SpondyloarthritisPRNewsWire • 06/27/22
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of MigrainePRNewsWire • 06/21/22
Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industryPRNewsWire • 06/17/22
SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in AdultsPRNewsWire • 06/17/22